CY1108459T1 - Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων - Google Patents

Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων

Info

Publication number
CY1108459T1
CY1108459T1 CY20081101217T CY081101217T CY1108459T1 CY 1108459 T1 CY1108459 T1 CY 1108459T1 CY 20081101217 T CY20081101217 T CY 20081101217T CY 081101217 T CY081101217 T CY 081101217T CY 1108459 T1 CY1108459 T1 CY 1108459T1
Authority
CY
Cyprus
Prior art keywords
polypalpteses
akt
akt3
relates
nuclear acids
Prior art date
Application number
CY20081101217T
Other languages
English (en)
Inventor
Kun Guo
Marco F Pagnoni
Kenneth L Clark
Yuri D Ivashchenko
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of CY1108459T1 publication Critical patent/CY1108459T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με πρωτεΐνες και πολυπεπτίδια ανθρώπινης Akt3. Η εφεύρεση επίσης σχετίζεται με απομονωμένα νουκλεϊκά οξέα που κωδικεύεουν ανθρώπινη Akt3, με φορείς που τα περιέχουν και με τις θεραπευτικές χρήσεις αυτών, ιδίως για γονιδιακή θεραπεία. Η έκφραση της Akt3 αναστέλλει τον κυτταρικό θάνατο που συνδέεται με υποξία, απόπτωση ή νέκρωση.
CY20081101217T 1999-03-19 2008-10-27 Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων CY1108459T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12510899P 1999-03-19 1999-03-19
EP00917899A EP1144600B1 (en) 1999-03-19 2000-03-14 Akt-3 nucleic acids, polypeptides, and uses thereof

Publications (1)

Publication Number Publication Date
CY1108459T1 true CY1108459T1 (el) 2013-09-04

Family

ID=22418217

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101217T CY1108459T1 (el) 1999-03-19 2008-10-27 Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων

Country Status (18)

Country Link
EP (1) EP1144600B1 (el)
JP (1) JP4237945B2 (el)
KR (1) KR100700908B1 (el)
AT (1) ATE402995T1 (el)
AU (1) AU782448B2 (el)
BR (1) BR0009170A (el)
CA (1) CA2343074C (el)
CY (1) CY1108459T1 (el)
DE (1) DE60039677D1 (el)
DK (1) DK1144600T3 (el)
ES (1) ES2310515T3 (el)
HK (1) HK1041288B (el)
IL (4) IL145514A0 (el)
NO (1) NO20014537L (el)
PT (1) PT1144600E (el)
SI (1) SI1144600T1 (el)
WO (1) WO2000056866A2 (el)
ZA (1) ZA200108414B (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
NZ514305A (en) 1999-04-16 2004-01-30 Univ Yale eNOS mutations useful for gene therapy and therapeutic screening
PL352859A1 (en) * 1999-06-11 2003-09-08 Aventis Pharmaceuticals Products Inc. Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt
WO2003063905A1 (fr) * 2002-01-31 2003-08-07 Center For Advanced Science And Technology Incubation, Ltd. Medicaments preventifs ou remedes pour maladies immunologiques
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
WO2005009470A1 (ja) * 2003-07-28 2005-02-03 Osaka Industrial Promotion Organization Ａｓｋ１阻害剤を有効成分とする心不全治療薬およびそのスクリーニング方法
EP2304439A4 (en) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc ANTI-phospho-AKT ANTIBODY
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
EP2588475B1 (en) 2010-07-02 2015-05-20 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
NZ729678A (en) 2014-09-24 2018-07-27 Gilead Sciences Inc Methods of treating non-alcoholic steatohepatitis using ask1 inhibitor in combination with a fxr agonist
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
CA3202893A1 (en) 2014-12-23 2016-06-30 Gilead Science, Inc. Processes for preparing ask1 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08109197A (ja) * 1994-10-07 1996-04-30 Sumitomo Electric Ind Ltd 白血病腫瘍拒絶抗原ペプチド
PT862622E (pt) * 1995-11-16 2005-01-31 Novartis Ag Metodo de rastreio para compostos que interagem com proteina cinase rac
US5958773A (en) * 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
GB9828375D0 (en) * 1998-12-22 1999-02-17 Janssen Pharmaceutica Nv Human akt-3
US6043090A (en) * 1999-03-23 2000-03-28 Isis Pharmaceuticals Inc. Antisense inhibition of human Akt-2 expression
CA2383592A1 (en) * 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
PL352859A1 (en) * 1999-06-11 2003-09-08 Aventis Pharmaceuticals Products Inc. Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt

Also Published As

Publication number Publication date
NO20014537L (no) 2001-10-31
IL145514A0 (en) 2002-06-30
PT1144600E (pt) 2008-10-10
EP1144600A2 (en) 2001-10-17
IL141984A0 (en) 2002-03-10
EP1144600B1 (en) 2008-07-30
BR0009170A (pt) 2002-04-30
SI1144600T1 (sl) 2008-12-31
ES2310515T3 (es) 2009-01-16
KR100700908B1 (ko) 2007-03-29
IL145514A (en) 2010-05-17
JP2002539781A (ja) 2002-11-26
JP4237945B2 (ja) 2009-03-11
WO2000056866A3 (en) 2001-02-15
HK1041288A1 (en) 2002-07-05
HK1041288B (zh) 2008-11-07
CA2343074C (en) 2010-09-21
KR20020011972A (ko) 2002-02-09
AU782448B2 (en) 2005-07-28
AU3880200A (en) 2000-10-09
DE60039677D1 (de) 2008-09-11
ATE402995T1 (de) 2008-08-15
ZA200108414B (en) 2003-03-26
IL190270A (en) 2012-12-31
CA2343074A1 (en) 2000-09-28
WO2000056866A2 (en) 2000-09-28
DK1144600T3 (da) 2008-11-24
NO20014537D0 (no) 2001-09-18
WO2000056866A9 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
CY1108459T1 (el) Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων
WO2003103589A3 (en) USE OF IL-21 IN THE TREATMENT OF CANCER AND OTHER THERAPEUTIC APPLICATIONS
BG100771A (en) Hematopoeic protein and ways and methods for its preparation
NO954466L (no) Adenovirale vektorer av animalsk opprinnelse samt deres anvendelse i genterapi
DK0559884T3 (da) Rekombinante virusvektorer til ekspression i muskelceller
DK0910647T3 (da) Human DNase i hyperaktive varianter
ES2194720T3 (es) Enzimas para el tratamiento de diabetes mellitus tipo i.
HUP0003533A2 (hu) Interleukin-18-at kötő fehérjék, előállításuk és alkalmazásuk
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
ATE392481T1 (de) Räumliche und temporäre kontrolle der genexpression mittels eines hitzeschockproteinpromotors in kombination mit lokaler hitze
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
BR0010563A (pt) Composições isoladas de células da pele e métodos para seu uso
EP0232523A3 (en) Dna sequences which encode for proteins with the biological activity of husi-type i inhibitors, their production by gene technology and drugs containing these proteins
TR200102985T2 (tr) Gen tedavisi teknikleri.
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
DE69831231D1 (de) Modulatoren von intrazellulären entzündungs-, zelltod- und zellüberlebenswegen, die card- und kinase-domänen enthalten
NZ516237A (en) Meth1 and meth2 polynucleotides and polypeptides
MXPA02009781A (es) Isoformas de esfingosina cinasa tipo 2 de mamifero, clonacion, expresion y metodos de uso de las mismas.
DE602005021159D1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
WO2002014369A3 (en) Human kininogen d5 domain polypeptides and their use
UA84831C2 (ru) Производные фактора коагуляции vii
ATE258801T1 (de) Matrixprotein zusammensetzungen um apoptose zu induzieren
BR0108187A (pt) Moléculas trade e usos relacionados com as mesmas